The Browne Jacobson-sponsored roundtable revealed that true partnership is the way forward to allow innovation and investment to flow both ways
The Investment session at the Healthcare World Dubai Forum followed a Healthcare World and Browne Jacobson White Paper on investment into the UK health economy. The debate was designed as a practical follow-up to take the paper’s recommendations and pressure-test them with UAE operators, investors, and UK NHS leaders who have tried, and sometimes failed, to make collaboration work.
The concept was simple – the UK and the UAE can do more together in health, not just via investment but through partnership that shares expertise and capability in both directions. The panellists acknowledged that there were areas of expertise in both regions that were of specific value and could lead to greater co-operation between the two countries. The UK has decades of experience of primary care as a gatekeeper. The UAE has learned how to procure, and operationalise at pace. With so much experience around the table, the experts debated the very real challenges to success, but there was a sense that it was achievable if taken slowly via clearly designed routes to build trust and confidence on both sides.
Current barriers to success In the UK, the NHS’s challenges are well-known. As Chair Steve Gardner, Managing Director of Healthcare World said: “It’s no secret that the NHS is having a few small issues at the moment and that outside help would be very much appreciated.” Yet it was acknowledged that in such a huge organisation with no central front door, there are huge obstacles in convincing some NHS leaders that change can also bring much needed revenue and more up to date ideas. In the UAE, several contributors described a system with worldclass assets alongside a payment and delivery model that can make specialist access too easy, and therefore too expensive, in the long run. One clinician compared it to the UK’s maturity: the Gulf has built impressive facilities quickly, but sustainability is now a major focus.
However, both systems – one mature and one relatively young – are facing the new reality in healthcare. There is a pressing if not urgent need to move healthcare out of hospital to manage rising costs, and overutilisation in Dubai’s case, along with incorporating digital and AI tools into both systems with the concurrent associated costs. The debate over investment An interesting point that came out of the discussion was the understanding or definition of the word ‘investment’. When UK organisations say they want investment, Gulf investors hear equity and revenue. For the NHS, investment can mean everything from research partnerships to estate development to licensing IP and often without a consistent model.
Panellists suggested expanding the understanding of the concept of investment. If investment can also mean education, staffing models, service redesign, shared research platforms, or codevelopment of technology, it would bring in a much wider group of organisations looking to contribute. This point echoed the White Paper recommendation about making the route understandable for any potential investor or contributor to follow.
For the NHS, the word ‘commercialisation’ carries a negative concept, contrary to the selfless values of the founding principle of the UK health service. One contributor suggested NHS trusts are not clear what commercialisation means in practice or what would be considered acceptable to the leadership. As a result, investors do not get a clear proposition, and NHS leaders do not feel they have permission or the internal capability to move ahead.
One former NHS leader described this missing commercial culture inside the system as a practical barrier to partnership. Any external involvement is quickly interpreted as privatisation which is contrary to the ethos of the organisation and its champions. The service was built on free care ‘at the time of need’, and many staff still experience commercial language as a threat to that moral purpose. But another to success is a reality. One contributor described current NHS procurement varying from trust to trust with changing priorities from the top down. As a result, the panellists felt that concrete guidance is a necessity for investor confidence and success. They defined it as guidance similar to a NICE pathway, allowing a partner to selfidentify their category, whether tech, clinical service, education, infrastructure, and then be routed to the right decision-makers with clarity on timescales and risk.
The structure in the UAE has a clear pathway that could be achieved in the UK if the single front door system is adopted. Many of the speakers described how Dubai attracts providers and operators with a clarity and pace that simplifies the process. One operator told the story of entering Dubai after being approached by the investment ecosystem, given a clear master plan, directed to an underserved zone, and offered tangible incentives. The same speaker described the difference in that the authorities acted as partners and not simply regulators. The feeling around the table was that the UK could borrow the concept that someone owns the relationship, someone guides the investor, and the system signals that it wants the partnership to succeed. contributor argued that the culture is shifting, driven by international
exposure and a growing awareness that partnership can be a route to reinvestment rather than erosion. The panel concluded that the system should find better ways to translate innovation and capability into sustainable income without abandoning its core principles.
The single front door
One of the routes discussed was the creation of a single front door to resolve the confusion felt by potential operators and investors alike. A UAE operator described repeated attempts to enter the UK market, getting stuck on data access and bureaucracy, and then simply losing momentum. Another compared it unfavourably with Australia’s approach in the region which boasts visible commissioning teams and clear pathways. Again this reality reflected one of the White Paper’s recommendations: a central business development function supported by people who understand commercial structures and can help trusts move faster without feeling exposed. Several UK participants stressed that this structure gives investors the necessary confidence that due diligence is possible and a route
Opportunities in each region
There was a consensus around the table that the NHS offers scale and credibility. Several participants pointed to the UK’s depth of clinical acuity and the sheer variety of cases that can support research, trials and innovation. For the global healthcare sector, the UK is a powerful testbed if there is a clear route in. In the same way, the participants recognised that the UAE embraces innovation and offers rapid routes alongside investment models. Whether it’s designing and building hospitals or clinics, or piloting new services, the speed at which the country accelerates partners is only to be admired.
Specific opportunity areas were identified:
• Primary care and community services As the UAE looks to make its health system more sustainable, the UK’s long-standing primary care ‘gatekeeper’ model is attracting fresh interest. The challenge is not whether it works, but how to adapt it locally without importing the frustrations that have built up around it in the UK.
• Mental health services Demand for mental health care is rising fast across the UAE, creating interest in scalable models that expand access quickly. UK providers shared examples of how private operators can still deliver NHS-funded care, offering a potential blueprint for cross border service design, not just technology transfer.
• Digital platforms and patient education Several UK digital tools are already designed to scale, with localisation including Arabic language adaptation relatively straightforward. This ability to adapt content quickly changes the economics of adoption and makes partnership more viable.
• Research and clinical trials Many UK organisations now combine care delivery with active research programmes. As the UAE looks to strengthen its research base, this creates a natural opportunity for collaboration, particularly if data governance and consent frameworks are built in from the outset, rather than added later.
• Outcomes data and benchmarking UK examples of publishing outcomes data show how transparency can support patient choice and clinical governance. Similar shared outcomes infrastructure could strengthen trust and accountability in the Gulf, provided incentives and oversight are designed carefully
Gulf investors described practical barriers in the UK including difficulty accessing reliable data for due diligence, contracts that are short-term and offer no volume certainty, and commercial frameworks that do not provide enough confidence for long-term investment. One compared the UK unfavourably with the relative transparency provided by DRG-based systems in parts of the Gulf, where the overall shape of reimbursement is easier to model.
Another participant described proposing a simple real-estate model involving the purchase of NHS-owned land and leasing it back, but meeting resistance. This objection was not because the approach was unsound, but because it was unfamiliar and therefore perceived as risky within a public-sector environment. The example clarified the fact that the NHS has not decided what kind of partnerships it will consider and cannot consider ones that fall outside traditional healthcare concepts.
One of the most helpful contributions came from a participant reflecting on Saudi’s approach to market entry. In KSA there is a national route that takes time but delivers scale, and there is a cluster route that starts smaller, proves value, and then expands. Several people felt that this method might be the best approach for the NHS.
For the NHS, starting with a handful of trusts that already have commercial leadership, clear governance and are open to opportunity can create precedent without forcing the whole system to move at once. For UAE partners, starting with defined pilots in areas where value is obvious and where public sensitivity is lower can build confidence and reduce the privatisation anxiety that still hangs over such discussions.
UK–UAE collaboration is already happening in pockets such as life sciences investment, branded clinical models, education partnerships, and service delivery. The Browne Jacobson/ Healthcare World White Paper recommendations are a starting point for a National Health Service in need of reform to take the first steps towards working with partners for the greater and global good.
Have some thoughts on the topic? Share them with the community here